Search clinical trials for: BI 655066 (very high i.v. dose)

Total 116 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
Sinovac Biotech Co., Ltd

Completed

Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine

Poliomyelitis

China
Suzanna L Attia
Fogarty International Center of the National Institute of Health

Completed

Nutritional Impact of Moringa Oleifera Leaf Supplementation in Mothers and Children

Malnutrition | Wasting | Growth Failure

Kenya
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders

Urination Disorders
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Healthy

Germany
Jiangsu Province Centers for Disease Control and...
Beijing Minhai Biotechnology Co., Ltd

Completed

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.

Polio and Post-Polio Syndrome

China
American Heart Association

Completed

Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control

Glycemic Control

United States
Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
Biocad

Active, not recruiting

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (ELEFTA)

Axial Spondyloarthritis

Russian Federation
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland
Far Eastern Memorial Hospital

Completed

Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot

Hemorrhage | Peptic Ulcer

Taiwan
Stanford University
Santen Inc.

Withdrawn

Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)

Panuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis

United States
Boehringer Ingelheim

Completed

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Alan Barkun
Pendopharm

Completed

The Bowel CLEAnsing: A National Initiative (B-CLEAN)

Subjets Requiring a Colonoscopy

Canada
University Hospital, Ghent

Completed

Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults (IPV-004)

Poliomyelitis

Belgium
Johns Hopkins University

Completed

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

Healthy

United States
Boehringer Ingelheim

Completed

Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers

Healthy

Germany
BioInvent International AB

Terminated

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
University of Monastir

Completed

Titrated Versus High and Low Dose Nebulized Morphine to Reduce Pain in Emergency Settings (TIMORNEB)

Acute Pain | Post-Traumatic Headache

Tunisia
Brown University
The Miriam Hospital; Rhode Island Hospital

Terminated

First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras

Colorectal Cancer

United States
Iovance Biotherapeutics, Inc.

Active, not recruiting

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Boehringer Ingelheim

Completed

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Healthy
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Anemia | Dialysis

Hong Kong, United States, Singapore, Russian Federation
JDP Therapeutics, Inc.
Algorithme Pharma Inc

Completed

Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg

Acute Urticaria

Canada
Stanford University
Washington University School of Medicine; Duke University; University of Washington and other collaborators

Enrolling by invitation

Antibiotic Prophylaxis in Rhinoplasty

Nasal Obstruction | Nasal Surgical Procedures

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers

Healthy
University of Nebraska

Completed

The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

Angioedema | Urticaria | Swelling | Hives

United States
Latin American Cooperative Oncology Group
Merck Sharp & Dohme LLC

Active, not recruiting

Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers (SMART-KEY)

Squamous Cell Carcinoma of Larynx

Brazil
King Chulalongkorn Memorial Hospital

Recruiting

High Dose Oral Omeprazole in High Risk UGIB

GI Bleeding

Thailand
Yale University

Recruiting

IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate

Nicotine Dependence

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, France, Guatemala, Italy, Korea, Republic of, Mexico, Poland, Russian Federation
Essentialis, Inc.

Withdrawn

Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline

Hypertriglyceridemia
Boehringer Ingelheim

Completed

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Healthy

China
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
University Hospital Carl Gustav Carus
German Research Foundation

Terminated

Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR (AML)

Leukemia, Myeloid, Acute

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Brown University
Lifespan; SouthCoast Medical Group; Memorial hospital

Completed

BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

Metastatic Pancreatic Cancer

United States
University Hospital, Bonn

Completed

Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children (HIT-REZ-2005)

Ependymomas | Recurrent Brain Tumors | Supratentorial PNETs | Medulloblastomas

Germany
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Vancouver General Hospital
Heart and Stroke Foundation of Canada; Vancouver Coastal Health Research Institute

Completed

Aminophylline in Bradyasystolic Cardiac Arrest

Cardiac Arrest

Canada
Yale University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

Heart Failure

United States
University of Pittsburgh
Genentech, Inc.

Completed

Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer

Cancer

United States
Norwegian University of Science and Technology

Completed

Treatment of Latent Autoimmune Diabetes of the Adult (LADA)

Diabetes

Norway
Children's Hospital of Philadelphia
Gateway for Cancer Research

Completed

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Osteosarcoma | Nephrotoxicity | Ototoxicity

United States
Angiochem Inc

Not yet recruiting

ANG1005 in Leptomeningeal Disease From Breast Cancer (ANGLeD)

Brain Metastases | Leptomeningeal Metastases | HER2-negative Breast Cancer | Leptomeningeal Carcinomatosis
Military Institute of Medicine, Poland

Completed

Non-invasive Haemodynamic Assessment in Hypertension (FINE-PATH)

Arterial Hypertension

Poland

Search clinical trials for: BI 655066 (very high i.v. dose)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations